MXPA06004299A - Derivados de arilespirofuropiridina. - Google Patents
Derivados de arilespirofuropiridina.Info
- Publication number
- MXPA06004299A MXPA06004299A MXPA06004299A MXPA06004299A MXPA06004299A MX PA06004299 A MXPA06004299 A MX PA06004299A MX PA06004299 A MXPA06004299 A MX PA06004299A MX PA06004299 A MXPA06004299 A MX PA06004299A MX PA06004299 A MXPA06004299 A MX PA06004299A
- Authority
- MX
- Mexico
- Prior art keywords
- aryl derivatives
- spirofuropyridine
- spirofuropyridine aryl
- compounds
- derivatives
- Prior art date
Links
- 125000003118 aryl group Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51289303P | 2003-10-21 | 2003-10-21 | |
| PCT/GB2004/004484 WO2005042538A1 (en) | 2003-10-21 | 2004-10-21 | Spirofuropyridine aryl derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA06004299A true MXPA06004299A (es) | 2006-06-05 |
Family
ID=34549233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA06004299A MXPA06004299A (es) | 2003-10-21 | 2004-10-21 | Derivados de arilespirofuropiridina. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7544693B2 (enExample) |
| EP (1) | EP1678183A1 (enExample) |
| JP (1) | JP4855264B2 (enExample) |
| KR (1) | KR20060094962A (enExample) |
| CN (1) | CN100494202C (enExample) |
| AU (1) | AU2004285751B2 (enExample) |
| BR (1) | BRPI0415546A (enExample) |
| CA (1) | CA2543436A1 (enExample) |
| IL (1) | IL174700A0 (enExample) |
| MX (1) | MXPA06004299A (enExample) |
| NO (1) | NO20062307L (enExample) |
| NZ (1) | NZ546413A (enExample) |
| WO (1) | WO2005042538A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005022788A1 (de) * | 2005-05-12 | 2006-11-23 | Henkel Kgaa | Mittel zum Färben von keratinhaltigen Fasern |
| SA08290475B1 (ar) | 2007-08-02 | 2013-06-22 | Targacept Inc | (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه |
| TW201031664A (en) | 2009-01-26 | 2010-09-01 | Targacept Inc | Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide |
| WO2018210229A1 (zh) * | 2017-05-18 | 2018-11-22 | 南京明德新药研发股份有限公司 | α-7尼古丁乙酰胆碱受体激动剂及应用 |
| CN111386272B (zh) | 2017-10-27 | 2023-01-06 | 费森尤斯卡比肿瘤学有限公司 | 一种改进的瑞博西尼及其盐的制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR013184A1 (es) * | 1997-07-18 | 2000-12-13 | Astrazeneca Ab | Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis |
| SE9900100D0 (sv) * | 1999-01-15 | 1999-01-15 | Astra Ab | New compounds |
| US6569865B2 (en) * | 2001-06-01 | 2003-05-27 | Astrazeneca Ab | Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine |
| WO2002096912A1 (en) | 2001-06-01 | 2002-12-05 | Astrazeneca Ab | Novel ligand for nicotinic acetylcholine receptors useful in therapy |
| JP2005510482A (ja) * | 2001-10-16 | 2005-04-21 | アストラゼネカ・アクチエボラーグ | 線維筋痛症候群の治療方法 |
| BR0309343A (pt) * | 2002-04-18 | 2005-02-15 | Astrazeneca Ab | Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas |
| JP4523775B2 (ja) * | 2002-04-18 | 2010-08-11 | アストラゼネカ・アクチエボラーグ | 複素環化合物 |
| BR0309342A (pt) * | 2002-04-18 | 2005-02-15 | Astrazeneca Ab | Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas |
-
2004
- 2004-10-21 JP JP2006536175A patent/JP4855264B2/ja not_active Expired - Fee Related
- 2004-10-21 WO PCT/GB2004/004484 patent/WO2005042538A1/en not_active Ceased
- 2004-10-21 NZ NZ546413A patent/NZ546413A/en unknown
- 2004-10-21 US US10/575,590 patent/US7544693B2/en not_active Expired - Fee Related
- 2004-10-21 AU AU2004285751A patent/AU2004285751B2/en not_active Ceased
- 2004-10-21 KR KR1020067007612A patent/KR20060094962A/ko not_active Ceased
- 2004-10-21 BR BRPI0415546-7A patent/BRPI0415546A/pt not_active IP Right Cessation
- 2004-10-21 CN CNB2004800311537A patent/CN100494202C/zh not_active Expired - Fee Related
- 2004-10-21 MX MXPA06004299A patent/MXPA06004299A/es active IP Right Grant
- 2004-10-21 CA CA002543436A patent/CA2543436A1/en not_active Abandoned
- 2004-10-21 EP EP04768999A patent/EP1678183A1/en not_active Withdrawn
-
2006
- 2006-03-30 IL IL174700A patent/IL174700A0/en unknown
- 2006-05-22 NO NO20062307A patent/NO20062307L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0415546A (pt) | 2006-12-26 |
| NO20062307L (no) | 2006-07-19 |
| WO2005042538A1 (en) | 2005-05-12 |
| US20070072887A1 (en) | 2007-03-29 |
| US7544693B2 (en) | 2009-06-09 |
| CN1871241A (zh) | 2006-11-29 |
| CN100494202C (zh) | 2009-06-03 |
| JP2007509121A (ja) | 2007-04-12 |
| KR20060094962A (ko) | 2006-08-30 |
| AU2004285751B2 (en) | 2008-07-24 |
| AU2004285751A1 (en) | 2005-05-12 |
| IL174700A0 (en) | 2006-08-20 |
| CA2543436A1 (en) | 2005-05-12 |
| EP1678183A1 (en) | 2006-07-12 |
| NZ546413A (en) | 2009-12-24 |
| JP4855264B2 (ja) | 2012-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL164511A0 (en) | Heterocyclic compounds | |
| IL164613A0 (en) | Thienyl compounds | |
| DE60334536D1 (de) | Furylverbindungen | |
| SE0202463D0 (sv) | Novel compounds | |
| AP1902A (en) | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives and their use as antibacterials | |
| UA84712C2 (en) | N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors | |
| MY142768A (en) | Gfat inhibitors | |
| MX2009006742A (es) | Inhibidores acilaminopirazoles como fgfr. | |
| GB0129476D0 (en) | Organic compounds | |
| MY134701A (en) | Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods | |
| WO2005021544A3 (en) | N3-substituted imidazopyridine-derivatives as c-kit inhibitors | |
| TW200503998A (en) | Phenyl compounds | |
| AU2002249890A1 (en) | Carboline derivatives | |
| MY138466A (en) | Aminoalkoxyndoles as 5-ht6-receptor ligands for the treatment of cns-disorders | |
| IL173810A0 (en) | Imidazopyridine derivatives and pharmaceutical compositions containing the same | |
| AP2002002466A0 (en) | 3-heterocycliylpropanohydroxamic acid PCP INHIBITORS. | |
| SE0203070D0 (en) | Novel compounds | |
| GB0229081D0 (en) | Multifunctional cationic photoinitiators, their preparation and use | |
| MXPA05010651A (es) | Compuestos de pirazol. | |
| MY139228A (en) | Imidazolinylmethyl aralkylsulfonamides | |
| SE0203302D0 (sv) | Novel Compounds | |
| MXPA05010650A (es) | Pirazoles sustituidos. | |
| MXPA04009421A (es) | Compuestos de tiazol-2-ilimina como inhibidores de la pde-7. | |
| MXPA06003345A (es) | Derivados de aminopiridina como inhibidores de la no-sintasa inducible. | |
| IL173895A0 (en) | Imidazopyridine derivatives and pharmaceutical compositions containing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration | ||
| HH | Correction or change in general |